Loading...

Pluristem Therapeutics

DB:PJTA
Snowflake Description

High growth potential with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
PJTA
DB
$79M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. The last earnings update was 76 days ago. More info.


Add to Portfolio Compare Print
  • Pluristem Therapeutics has significant price volatility in the past 3 months.
PJTA Share Price and Events
7 Day Returns
-13.3%
DB:PJTA
-2.7%
DE Biotechs
1.5%
DE Market
1 Year Returns
-52.3%
DB:PJTA
-10.6%
DE Biotechs
-6.2%
DE Market
PJTA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Pluristem Therapeutics (PJTA) -13.3% -44.9% -51.9% -52.3% -70.7% -81.6%
DE Biotechs -2.7% 3.8% -8.5% -10.6% 47.4% 10.3%
DE Market 1.5% 6% 8.5% -6.2% 10.7% 15.3%
1 Year Return vs Industry and Market
  • PJTA underperformed the Biotechs industry which returned -10.6% over the past year.
  • PJTA underperformed the Market in Germany which returned -6.2% over the past year.
Price Volatility
PJTA
Industry
5yr Volatility vs Market

PJTA Value

 Is Pluristem Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Pluristem Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is €0.4698.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Pluristem Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Pluristem Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:PJTA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.25
NasdaqCM:PSTI Share Price ** NasdaqCM (2019-04-23) in USD $0.54
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.6x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Pluristem Therapeutics.

DB:PJTA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:PSTI Share Price ÷ EPS (both in USD)

= 0.54 ÷ -0.25

-2.18x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Pluristem Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Pluristem Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Pluristem Therapeutics's expected growth come at a high price?
Raw Data
DB:PJTA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.18x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
71.6%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Pluristem Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Pluristem Therapeutics's assets?
Raw Data
DB:PJTA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.13
NasdaqCM:PSTI Share Price * NasdaqCM (2019-04-23) in USD $0.54
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:PJTA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:PSTI Share Price ÷ Book Value per Share (both in USD)

= 0.54 ÷ 0.13

4.17x

* Primary Listing of Pluristem Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Pluristem Therapeutics is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Pluristem Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Pluristem Therapeutics has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

PJTA Future Performance

 How is Pluristem Therapeutics expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
71.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Pluristem Therapeutics expected to grow at an attractive rate?
  • Pluristem Therapeutics's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Pluristem Therapeutics's earnings growth is expected to exceed the Germany market average.
  • Pluristem Therapeutics's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:PJTA Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:PJTA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 71.6%
DB:PJTA Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 62.1%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:PJTA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:PJTA Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-06-30 187 93 2
2022-06-30 127 52 2
2021-06-30 72 -10 2
2020-06-30 33 -30 2
2019-06-30 3 -36 1
DB:PJTA Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 0 -28 -28
2018-09-30 0 -25 -28
2018-06-30 0 -21 -26
2018-03-31 0 -22 -24
2017-12-31 0 -22 -30
2017-09-30 -23 -29
2017-06-30 -22 -28
2017-03-31 0 -21 -27
2016-12-31 0 -21 -26
2016-09-30 3 -19 -24
2016-06-30 3 -19 -23
2016-03-31 3 -18 -22

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Pluristem Therapeutics's earnings are expected to grow significantly at over 20% yearly.
  • Pluristem Therapeutics's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:PJTA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Pluristem Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:PJTA Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-06-30 0.58 0.85 0.30 2.00
2022-06-30 0.33 0.53 0.13 2.00
2021-06-30 -0.07 -0.07 -0.07 1.00
2020-06-30 -0.21 -0.21 -0.21 1.00
2019-06-30 -0.29 -0.28 -0.29 2.00
DB:PJTA Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.25
2018-09-30 -0.25
2018-06-30 -0.25
2018-03-31 -0.24
2017-12-31 -0.31
2017-09-30 -0.32
2017-06-30 -0.32
2017-03-31 -0.32
2016-12-31 -0.33
2016-09-30 -0.30
2016-06-30 -0.29
2016-03-31 -0.29

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Pluristem Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Pluristem Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Pluristem Therapeutics has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

PJTA Past Performance

  How has Pluristem Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Pluristem Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Pluristem Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Pluristem Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Pluristem Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Pluristem Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Pluristem Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:PJTA Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 0.05 -27.98 10.78 24.40
2018-09-30 0.05 -27.53 11.57 23.78
2018-06-30 0.05 -26.13 12.13 21.70
2018-03-31 0.05 -24.16 11.39 20.24
2017-12-31 0.05 -30.49 10.61 20.19
2017-09-30 -28.88 9.14 19.76
2017-06-30 -27.81 7.94 20.08
2017-03-31 0.00 -27.00 7.74 19.86
2016-12-31 0.00 -26.34 7.50 19.28
2016-09-30 2.75 -23.69 7.60 19.42
2016-06-30 2.85 -23.25 7.52 18.55
2016-03-31 2.94 -22.34 7.34 18.46
2015-12-31 3.04 -22.36 7.22 18.80
2015-09-30 0.38 -24.64 7.19 18.34
2015-06-30 0.38 -24.68 7.38 18.25
2015-03-31 0.38 -25.58 8.02 18.51
2014-12-31 0.38 -27.63 9.03 19.26
2014-09-30 0.38 -28.09 9.49 19.49
2014-06-30 0.38 -26.93 9.64 18.58
2014-03-31 0.38 -27.73 8.62 20.11
2013-12-31 0.48 -24.13 7.25 18.22
2013-09-30 0.58 -21.92 6.69 16.77
2013-06-30 0.68 -21.16 6.54 16.34
2013-03-31 0.69 -18.30 6.37 13.27
2012-12-31 0.72 -16.79 7.14 11.22
2012-09-30 0.76 -14.30 6.99 8.63
2012-06-30 0.72 -14.79 7.13 8.60

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Pluristem Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Pluristem Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Pluristem Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Pluristem Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Pluristem Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

PJTA Health

 How is Pluristem Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Pluristem Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Pluristem Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Pluristem Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Pluristem Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Pluristem Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Pluristem Therapeutics Company Filings, last reported 3 months ago.

DB:PJTA Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 15.19 0.00 14.71
2018-09-30 21.53 0.00 21.72
2018-06-30 28.51 0.00 29.90
2018-03-31 33.23 0.00 33.38
2017-12-31 36.96 0.00 35.29
2017-09-30 24.36 0.00 20.75
2017-06-30 30.25 0.00 26.11
2017-03-31 35.62 0.00 32.49
2016-12-31 25.11 0.00 21.37
2016-09-30 32.90 0.00 28.76
2016-06-30 38.16 0.00 32.21
2016-03-31 43.11 0.00 37.43
2015-12-31 49.35 0.00 43.10
2015-09-30 52.35 0.00 46.69
2015-06-30 58.14 0.00 52.04
2015-03-31 45.56 0.00 41.09
2014-12-31 49.14 0.00 45.24
2014-09-30 53.70 0.00 46.05
2014-06-30 62.12 0.00 53.91
2014-03-31 65.96 0.00 60.12
2013-12-31 60.83 0.00 56.75
2013-09-30 54.79 0.00 48.67
2013-06-30 57.47 0.00 53.90
2013-03-31 64.02 0.00 59.83
2012-12-31 69.04 0.00 64.57
2012-09-30 72.19 0.00 68.31
2012-06-30 37.74 0.00 37.81
  • Pluristem Therapeutics has no debt.
  • Pluristem Therapeutics has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Pluristem Therapeutics has less than a year of cash runway based on current free cash flow.
  • Pluristem Therapeutics has less than a year of cash runway if free cash flow continues to grow at historical rates of 9% each year.
X
Financial health checks
We assess Pluristem Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Pluristem Therapeutics has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

PJTA Dividends

 What is Pluristem Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Pluristem Therapeutics dividends.
If you bought €2,000 of Pluristem Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Pluristem Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Pluristem Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:PJTA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:PJTA Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-06-30
2022-06-30
2021-06-30
2020-06-30
2019-06-30

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Pluristem Therapeutics has not reported any payouts.
  • Unable to verify if Pluristem Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Pluristem Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Pluristem Therapeutics has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Pluristem Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Pluristem Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Pluristem Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

PJTA Management

 What is the CEO of Pluristem Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Zami Aberman
COMPENSATION $592,834
AGE 64
TENURE AS CEO 2.1 years
CEO Bio

Mr. Zami Aberman has been Co-Chief Executive Officer of Pluristem Therapeutics Inc. since March 29, 2017. Mr. Aberman served as the Chief Executive Officer of Pluristem Therapeutics, Inc., (Alternate Name: Pluristem Life Systems Inc.) from September 26, 2005 to March 29, 2017. Mr. Aberman has been an Executive Chairman of Pluristem Therapeutics, Inc, since April 3. 2006 and has been its Executive Director since November 21, 2005. Mr. Aberman served as the President of Pluristem Therapeutics, Inc. from September 26, 2005 to February 5, 2014. He has over 20 years of experience in managing industrial companies, international marketing of breakthrough technological solutions to automotive, aerospace, metal industry and flat panel manufacturing, as well as experience in establishing and managing start-up companies active in the field of software development, chip development, advanced system development, flexible automation inspection and image processing. He served Chief Executive and Chairman positions in Israel, the USA, Europe, Japan and Korea. He operated within high-tech global companies in the fields of Automatic Optical Inspection, network security, Video over IP, software, chip design and robotic markets. Since 1996, Mr. Aberman founded and managed high-tech companies active in various fields. He served as the President of Elbit Vision Systems Ltd. and served as its Chief Executive Officer until December 26, 2004. Mr. Aberman served as President and Chief Executive Officer of Netect Ltd, specialized in the field of Internet security software. He was the Co-Founder, President and Chief Executive Officer of Associative Computing Ltd. He served as President and Chief Executive Officer of Robomatix Technologies Ltd., a public company (RBMXF.OB) from 1987 to 1996. He served as an Acting Chairman of Pluristem Therapeutics, Inc. since April 3, 2006. He served as Chairman of Display Inspection Systems Inc. specializing in laser based inspection machines. Mr. Aberman served as the Chairman of Rose Hi-tech Ltd. and VLScom Ltd. Mr. Aberman has been an Executive Director of Pluristem Therapeutics, Inc, He has been a Director of Alliance for Regenerative Medicine since October 2015. Mr. Aberman served as a Director of Ori Software Ltd. In 1992, Mr. Aberman was awarded the Rothschild Prize, for the development of a unique, laser based, flexible manufacturing system for the automotive industry, from the President of the State of Israel. Mr. Aberman holds a B.Sc. in Mechanical Engineering from Ben Gurion University in Israel.

CEO Compensation
  • Zami's compensation has been consistent with company performance over the past year.
  • Zami's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Pluristem Therapeutics management team in years:

2.1
Average Tenure
52.5
Average Age
  • The tenure for the Pluristem Therapeutics management team is about average.
Management Team

Zami Aberman

TITLE
Chairman & Co-CEO
COMPENSATION
$593K
AGE
64
TENURE
2.1 yrs

Yaky Yanay

TITLE
President
COMPENSATION
$443K
AGE
47
TENURE
2.1 yrs

Chen Franco-Yehuda

TITLE
CFO, Treasurer & Secretary
AGE
34
TENURE
0.1 yrs

Boaz Leshem

TITLE
Vice President Operations & Manufacturing
AGE
58
TENURE
1.3 yrs

Efrat Kaduri

TITLE
Director of Business
TENURE
5.3 yrs

Efrat Livne-Hadass

TITLE
Vice President of Human Resources
Board of Directors Tenure

Average tenure and age of the Pluristem Therapeutics board of directors in years:

13
Average Tenure
64.5
Average Age
  • The average tenure for the Pluristem Therapeutics board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Yaky Yanay

TITLE
President
COMPENSATION
$443K
AGE
47
TENURE
4.2 yrs

Doron Shorrer

TITLE
Lead Independent Director
COMPENSATION
$211K
AGE
65

Zami Aberman

TITLE
Chairman & Co-CEO
COMPENSATION
$593K
AGE
64
TENURE
13 yrs

Edwin Horwitz

TITLE
Chairman of the Scientific Advisory Board

Hava Meretzki

TITLE
Director
COMPENSATION
$149K
AGE
49
TENURE
15.5 yrs

Israel Ben-Yoram

TITLE
Independent Director
COMPENSATION
$212K
AGE
57
TENURE
14.3 yrs

Isaac Braun

TITLE
Independent Director
COMPENSATION
$150K
AGE
65
TENURE
13.8 yrs

Mark Germain

TITLE
Independent Director
COMPENSATION
$202K
AGE
67
TENURE
11.9 yrs

Nachum Rosman

TITLE
Independent Director
COMPENSATION
$212K
AGE
72
TENURE
11.5 yrs

Jacob Rowe

TITLE
Member of the Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Pluristem Therapeutics insiders in the past 3 months.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
08. Apr 19 Buy Yaky Yanay Individual 08. Apr 19 08. Apr 19 71,429 €0.62 €44,405
08. Apr 19 Buy Israel Ben-Yoram Individual 08. Apr 19 08. Apr 19 71,429 €0.62 €44,405
08. Apr 19 Buy Zami Aberman Individual 08. Apr 19 08. Apr 19 71,429 €0.62 €44,405
08. Apr 19 Buy Doron Shorrer Individual 08. Apr 19 08. Apr 19 14,286 €0.62 €8,881
08. Apr 19 Buy Moria Kwiat Individual 08. Apr 19 08. Apr 19 28,571 €0.62 €17,762
08. Apr 19 Buy Isaac Braun Individual 08. Apr 19 08. Apr 19 50,000 €0.62 €31,084
X
Management checks
We assess Pluristem Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Pluristem Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

PJTA News

Simply Wall St News

PJTA Company Info

Description

Pluristem Therapeutics Inc., together with its subsidiary, Pluristem Ltd., operates as a bio-therapeutics company in Israel. It focuses on the research, development, clinical trial, and manufacture of cell therapeutic products and related technologies for the treatment of various ischemic, inflammatory, and hematologic conditions, as well as autoimmune disorders. The company develops PLacental eXpanded (PLX) cell therapy products, including PLX-PAD cells, which is Phase III clinical trial for the treatment of critical limb ischemia (CLI) in patients ineligible for revascularization, recovery after surgery for hip fracture, and acute radiation syndrome (ARS), as well as peripheral and cardiovascular, and orthopedic diseases. It also develops PLX-R18 cells that is in Phase I clinical trial for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as conducts various animal studies for the evaluation of PLX-R18 for the treatment of ARS. The company has collaborative research agreement with the Berlin-Brandenburg Center for Regenerative Therapies; a license and commercialization agreement for conducting clinical trials and commercialization of its PLX-PAD product in South Korea related to the treatment CLI and intermediate claudication; and nTRACK, a collaborative project with Leitat to examine gold nano particles labeling of stem cells. It also has a collaboration agreement with the NASA’s Ames Research Center to evaluate the potential of PLX cell therapies in preventing and treating medical conditions caused during space missions. Pluristem Therapeutics Inc. was founded in 2001 and is based in Haifa, Israel.

Details
Name: Pluristem Therapeutics Inc.
PJTA
Exchange: DB
Founded: 2001
$70,152,187
149,734,663
Website: http://www.pluristem.com
Address: Pluristem Therapeutics Inc.
Building No. 5,
MATAM Advanced Technology Park,
Haifa,
31905,
Israel
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM PSTI Common Stock Nasdaq Capital Market US USD 21. Jan 2003
DB PJTA Common Stock Deutsche Boerse AG DE EUR 21. Jan 2003
LSE 0KJI Common Stock London Stock Exchange GB USD 21. Jan 2003
TASE PSTI Common Stock The Tel-Aviv Stock Exchange IL ILS 21. Jan 2003
Number of employees
Current staff
Staff numbers
176
Pluristem Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/23 21:20
End of day share price update: 2019/04/23 00:00
Last estimates confirmation: 2019/04/23
Last earnings filing: 2019/02/06
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/06/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.